Glaukos CorpNYSE:GKOS
- LAST PRICE132.5300
- TODAY'S CHANGE (%)0.7600 (0.5768%)
- Bid / Lots132.5200/ 8
- Ask / Lots132.9500/ 8
- Open / Previous Close130.4000 / 131.7700
- Day Range
- 52 Week Range
- Volume164,954
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GKOS |
|---|---|---|
| 09:32 ET | 4860 | 129.21 |
| 09:33 ET | 746 | 129.31 |
| 09:35 ET | 2237 | 129.79 |
| 09:37 ET | 2531 | 130.04 |
| 09:39 ET | 610 | 130.61 |
| 09:42 ET | 500 | 130.635 |
| 09:46 ET | 200 | 130.805 |
| 09:48 ET | 592 | 130.79 |
| 09:50 ET | 3047 | 131.45 |
| 09:51 ET | 332 | 131.95 |
| 09:53 ET | 180 | 131.5359 |
| 09:55 ET | 1146 | 131.96 |
| 09:57 ET | 16550 | 131.965 |
| 10:00 ET | 500 | 131.93 |
| 10:02 ET | 840 | 131.64 |
| 10:04 ET | 400 | 131.785 |
| 10:06 ET | 700 | 131.83 |
| 10:08 ET | 100 | 131.615 |
| 10:09 ET | 2000 | 131.27 |
| 10:11 ET | 200 | 131.385 |
| 10:13 ET | 400 | 131.49 |
| 10:15 ET | 200 | 131.68 |
| 10:18 ET | 3959 | 131.6 |
| 10:20 ET | 200 | 131.54 |
| 10:22 ET | 715 | 131.27 |
| 10:24 ET | 6281 | 131.51 |
| 10:26 ET | 500 | 131.535 |
| 10:27 ET | 8536 | 130.975 |
| 10:29 ET | 1400 | 131.185 |
| 10:31 ET | 700 | 131.37 |
| 10:33 ET | 100 | 131.375 |
| 10:36 ET | 2205 | 131.99 |
| 10:38 ET | 780 | 132.25 |
| 10:40 ET | 2420 | 132.485 |
| 10:42 ET | 9053 | 132.745 |
| 10:44 ET | 2357 | 132.605 |
| 10:45 ET | 6000 | 132.305 |
| 10:47 ET | 1100 | 131.855 |
| 10:49 ET | 1200 | 131.58 |
| 10:51 ET | 2140 | 131.89 |
| 10:54 ET | 900 | 131.99 |
| 10:56 ET | 5964 | 131.825 |
| 10:58 ET | 1200 | 132.31 |
| 11:00 ET | 1900 | 132.37 |
| 11:02 ET | 1109 | 133.16 |
| 11:03 ET | 1464 | 133.5 |
| 11:05 ET | 702 | 133.065 |
| 11:07 ET | 1400 | 132.42 |
| 11:09 ET | 990 | 132.795 |
| 11:12 ET | 406 | 132.705 |
| 11:14 ET | 300 | 132.85 |
| 11:16 ET | 322 | 132.61 |
| 11:18 ET | 123 | 132.53 |
Oct 16, 2024
Oct 14, 2024
DJ Glaukos Is Maintained at Buy by Truist Securities, from 10:13AM ET on Monday Oct 14, 2024 by Dow Jones
10:13AM ET on Monday Oct 14, 2024 by Dow JonesGlaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting, from 7:00AM ET on Monday Oct 14, 2024 by Dow Jones
7:00AM ET on Monday Oct 14, 2024 by Dow Jones
Oct 9, 2024
Press Release: Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4, from 7:01AM ET on Wednesday Oct 09, 2024 by Dow Jones
7:01AM ET on Wednesday Oct 09, 2024 by Dow JonesGlaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4, from 7:00AM ET on Wednesday Oct 09, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Glaukos Corp | 7.2B | -41.4x | --- |
Repligen Corp | 7.8B | -3,348.4x | +15.08% |
Lantheus Holdings Inc | 7.5B | 18.9x | +35.30% |
Stevanato Group SpA | 5.9B | 39.9x | --- |
Inspire Medical Systems Inc | 5.7B | 1,006.0x | --- |
Masimo Corp | 7.7B | 98.8x | -15.37% |
Company Information
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Contact Information
- Headquarters
- 1 GLAUKOS WAYALISO VIEJO, CA, United States 92656
- Phone
- 949-367-9600
- Fax
- 949-367-9984
Executives
- Chairman of the Board, Chief Executive Officer
- Thomas Burns
- President, Chief Operating Officer
- Joseph Gilliam
- Chief Financial Officer, Senior Vice President
- Alex Thurman
- Chief Development Officer
- Tomas Navratil
- Lead Independent Director
- Mark Foley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.2B |
|---|---|
Revenue (TTM) | $341.7M |
Shares Outstanding | 55.0M |
Glaukos Corp does not pay a dividend. | |
Beta | 1.03 |
EPS | $-3.20 |
Book Value | $9.40 |
P/E Ratio | -41.4x |
Price/Sales (TTM) | 21.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.70% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
